Olon

Olon

Olon emerged from the Italian fine-chemicals tradition as a specialized contract development and manufacturing organization, serving pharmaceutical clients who outsource API production. The company's production footprint includes facilities in Capua, Rodano, Mulazzano, and Settimo Torinese, among others, supplemented by international sites. Olon supplies generic APIs and performs custom synthesis for proprietary drug programs, positioning itself across the full small-molecule lifecycle. The firm's portfolio covers anti-infectives, oncology, cardiovascular, and central nervous system therapies. Olon manufactures using fermentation-based processes, multi-step chemical synthesis, and high-containment suites for potent compounds. Its customer base includes major generic drugmakers and innovator pharmaceutical companies seeking European-based, non-Asian supply chain partners. Geographic reach extends from European regulators into FDA-inspected US markets and WHO-prequalified global health channels. A key differentiator is the breadth of Olon's technology stack — few independent API manufacturers operate both large-scale fermentation and synthetic chemistry under the same quality system. The company has invested in capacity expansions for high-potency APIs, notably corticosteroids and oncology drugs. Its structure as a standalone manufacturer, rather than a subsidiary of a pharma conglomerate, allows it to serve multiple competing drug companies simultaneously. Private equity ownership has shaped Olon's recent trajectory. Following a period under the Italian government's Golden Power review framework, the company has been positioned for growth through both organic investment and bolt-on acquisitions. This ownership structure distinguishes Olon from both publicly-traded CDMO peers and captive API divisions inside big pharma.